IOTA Pharmaceuticals


IOTA Pharmaceuticals
Fragment - based Drug Discovery
GBM Drug Bank
Glioma & Glioblastoma
WINDOW on Glioblastoma
IOTA Pharmaceuticals IOTA Pharmaceuticals

IOTA Pharmaceuticals announce the creation of the GBM Drug Bank to accelerate preclinical drug discovery for glioblastoma. Click here for Press Release. Click here for further information.

IOTA Pharmaceuticals Ltd is a Life Sciences company, based in Cambridge UK, applying state-of-the-art, industry-leading technologies to drug discovery projects.

We are currently partners in two European projects (total value of €18.5m), which are developing specific approaches in Fragment-based Lead Discovery and Natural Product Screening to clinical disease.

Human glioblastoma is our current therapeutic focus. Among other projects IOTA participates in the WINDOW Consortium in which we are the coordinators of a global glioblastoma research network and glioblastoma drug bank. You can find recent developments in glioblastoma research on our resource page.

Learn more about IOTA's involvement in the WINDOW Consortium here.

Register your interest in further collaboration on glioblastoma here.